20 May 2013
Keywords: zometa, cuts, risk, early-stage, breast, cancer, recurrence
Article | 22 September 2008
Novartis' Zometa (zoledronic acid) reduced the risk of local and distant recurrence in pre- and post-menopausal women with early-stage breast
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
22 September 2008
17 May 2013
© 2013 thepharmaletter.com